FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today it will participate in the New York Society for Gastrointestinal Endoscopy (NYSGE) 43rd Annual New York Course, and pre-conference activities at the New York Marriott Marquis Hotel from December 18 – 20, 2019.
Motus GI’s activities at NYSGE will include a hands-on training, sponsorship of a lunch symposium on addressing inadequate bowel preparation and in-booth live demonstrations of the Pure-Vu System. The Pure-Vu System is a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure.
Tim Moran, chief executive officer of Motus GI, commented, “The rate of insufficient bowel preparation for colonoscopies remains high despite the current standard of care. This leads to frequently rescheduled procedures and longer hospital stays, adding costs to both the patient and hospital. We look forward to demonstrating how the Pure-Vu System can fit into the colonoscopy procedural workflow to quickly, safely and effectively cleanse a patient’s colon. This allows a physician to perform a quality examination even when the patient does not or is not able to complete a successful bowel prep on his or her own.”
Additional details can be found below.
Hands-On Training on the Pure-Vu System
Date/Time: December 18, 2019 at 6:00 PM ET
Session: Yes You Can Do That! Adding More Endoscopy Skills to Your Practice
Presenter: Melissa Latorre, MD
Location: Lyceum Complex, Fifth Floor
Lunch Symposium on Inadequate Bowel Preparation: New Solutions to an Old Problem
Date/Time: December 19, 2019 at 12:00 PM ET
Session: Inadequate Bowel Prep, New Solutions to an Old Problem
Presenter: Brian Jacobson, MD.
Location: Westside Ballroom 1&2, Fifth Floor
In-Booth Live Demonstrations of the Pure-Vu System
Date/Time: December 19 – 20, 2019 from 9:45 AM – 4:00 PM ET
Presenter: Motus GI Staff
Location: Westside Ballroom 3&4, Booth# 300
About Motus GI and the Pure-Vu® System
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions. The Company’s flagship product is the Pure-Vu® System, a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to enable safe and rapid cleansing during the procedure while preserving established procedural workflow and techniques. Challenges with bowel preparation for inpatient colonoscopy represent a significant area of unmet need that directly affects clinical outcomes and increases the cost of care in a market segment that comprises approximately 1.5 million annual procedures in the U.S. and approximately 4 million annual procedures worldwide. Motus GI believes the Pure-Vu® System may improve outcomes and lower costs for hospitals by reducing the time to successful colonoscopy, minimizing delayed and incomplete procedures, and improving the quality of an exam. In clinical studies to date, the Pure-Vu® System significantly increased the number of patients with an adequate cleansing level, according to the Boston Bowel Preparation Scale Score, a validated assessment instrument.
This press release contains certain forward-looking statements. Forward-looking statements are based on the Company's current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms, including without limitation, risks inherent in the development and commercialization of potential products, uncertainty in the timing and results of clinical trials or regulatory approvals, maintenance of intellectual property rights or other risks discussed in the Company’s Form 10-K filed on March 26, 2019, and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.